A/Prof Sebastian Lunke is the Head of Division of Genetics and Genomics at the Victorian Clinical Genetics Services (VCGS) in Melbourne, Australia. Following his PhD in epigenetics and several years working as a post-doctoral research fellow at the University of Melbourne, where he developed assays for cancer genomics, he started re-training as a medical scientist with the Faculty of Science at the Royal College of Pathologist Australasia in 2014. Today, his team at VCGS constitutes one of the largest clinically accredited genomics laboratories in Australia, with a strong focus on translating novel technologies into clinical practice.

Professor Campbell is co-Head of the Women’s Cancer Program at the Peter MacCallum Cancer Centre and Professor in the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia and Principal investigator of the Lifepool study (www.lifepool.org). Professor Campbell has over 30 years research experience into the somatic and germline genetics of breast and ovarian cancer exemplified by seminal discoveries in the origins of ovarian cancer and the first identification of mutations in a PI3K pathway gene which are now among the most important therapeutic targets in cancer. He was a pioneer in applying next generation sequencing technology to the identification of new cancer predisposition genes and in population-based genetic testing for high-risk cancer predisposition genes.

Dr. Im received his PhD from University of Wisconsin-Madison. Then he joined Prof. Michael Synder’s lab at Stanford university. During his postdoc training, he developed human TF proteome array and utilized NGS to understand MDS, pulmonary hypertension and stem cell biology. he then joined Samsung SDS as an associate scientist in genomics division. He is currently serve as a head of science at Genome Opinion building NGS based diagnostics and therapeutic biomarkers identification project.